Search

Displaying results 7101 - 7110 of 10000 in total
  1. Drug

    Lysergic acid diethylamide

    go.drugbank.com/drugs/DB04829
    IllicitInvestigational

    Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. … However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.

    Synonyms: N,N-diethyllysergamide, N,N-diethyl-D-lysergamide
  2. Drug

    Meglutol

    go.drugbank.com/drugs/DB04377
    Experimental

    is the rate limiting enzyme in the biosynthesis of cholesterol. … An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids.

  3. Drug

    Fluindione

    go.drugbank.com/drugs/DB13136
    ApprovedWithdrawn

    Fluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.

  4. Drug

    Padoprazan

    go.drugbank.com/drugs/DB21689
    Experimental

    The usage of the INN stem '-prazan' in the name indicates that Padoprazan is a proton pump inhibitor, not dependent on acid activation. Padoprazan has a monoisotopic molecular weight of 405.12 Da.

  5. Drug

    Cholesteryl chloride

    go.drugbank.com/drugs/DB14045
    Experimental

    Cholesteryl chloride, also known as 3-chlorocholest-5-ene, is an organochloride derivative of cholesterol. It is presented as a liquid crystal that forms clockwise liquid crystals.

    Synonyms: 3-Chlorocholest-5-ene
  6. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.

  7. Drug

    TZP-102

    go.drugbank.com/drugs/DB16129
    Investigational

    TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).

  8. Drug

    alpha-Conotoxin VC 1.1

    go.drugbank.com/drugs/DB05724
    Experimental

    Categories: Complex Mixtures
  9. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  10. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.